The tyrosine kinase receptor Met and its ligand, hepatocyte growth factor (HGF)/scatter factor are involved in the etiology and progression of a number of human cancers. Coexpression of Met and HGF in mesenchymal cells increases the tumorigenic and metastatic potential of the cells. In the studies described here, we used dierential display screening to identify changes in gene expression that are initiated by Met/HGF, and that may lead to these phenotypes. We learned that Met/ HGF signaling resulted in greatly decreased ®bronectin mRNA production in three dierent human and mouse tumor cell lines; these decreases in ®bronectin mRNA were paralleled by decreases in ®bronectin protein. We also found a progressive decrease in ®bronectin in tumor explants and metastases derived from the Met/HGF transformed cells. The absence of ®bronectin expression is a frequent cancer phenotype; our results indicate that decreases in ®bronectin correlate with, but are not essential for, MetHGF/SF-mediated tumorigenesis.
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Results and discussion
Met is a 190 kDa tyrosine kinase receptor that is encoded by the c-met proto-oncogene and is expressed predominantly in epithelial and endothelial cells (for review, see Jeers et al., 1996c) . Its ligand, hepatocyte growth factor (HGF), also known as scatter factor (SF) because of its ability to scatter cells in vitro, is produced mainly by mesenchymal cells , and consequently, interacts with the Met receptor in a paracrine or endocrine manner. Met-HGF/SF signaling is essential for many normal biological processes including embryogenesis Giancotti and Mainiero, 1994; Schmidt et al., 1995) , neural induction (Streit et al., 1995) , kidney development (Santos et al., 1994) , tissue generation (Matsumoto and Nakamura, 1993) , angiogenesis (Grant et al., 1993) , and would healing (Nusrat et al., 1994) . These in vivo activities are mimicked to some extent in cultured cells, where Met-HGF/SF are potent stimulators of cell growth, cell motility, and cell morphogenesis (Jeers et al., 1996c; Rosen et al., 1994) .
Aberrant Met-HGF/SF signaling is implicated in a large number of human cancers (Jeers et al., 1996c) . At least two mechanisms are involved in the etiology of these cancers: mutation of the Met receptor to activate the receptor independent of ligand , and coexpression of Met and HGF/SF to establish a transforming autocrine/paracrine growth loop (Jeers et al., 1996b; Rong et al., 1993a Rong et al., ,b, 1994 . The former mechanism is important in the generation of both inherited and spontaneous forms of papillary renal carcinoma , while the latter mechanism may be causative in a wide variety of malignant diseases, such as sarcomas (Rong et al., 1993a) , carcinomas (Jeers et al., 1996c) , melanomas (Saitoh et al., 1994) , glioblastoma (Koochekpour et al., 1997; Laterra et al., 1997) , and even multiple myeloma (Borset et al., 1996) . Both mechanisms have been reproduced in cultured cells by stably transfecting cells with activated, mutant forms of Met , or by co-transfecting Met and HGF/SF (Jeers et al., 1996a,b; Rong et al., 1994) , thereby rendering the cells tumorigenic and capable of invasive growth and metastasis.
While the downstream signaling pathways for Met have been characterized (Faletto et al., 1993; Weidner et al., 1995) , those involved in Met-HGF/SF-mediated tumorigenesis are largely unknown. In the experiments described here, we have used dierential display screening to identify changes in gene expression initiated by autocrine Met-HGF/SF signaling in SK-LMS human leiomeiosarcoma cells. These cells normally produce high levels of Met but virtually no HGF/SF, and in addition, they are non-metastatic and only weakly tumorigenic in nude mice. However, when they stably express exogenous HGF/SF generating an autocrine Met signaling loop, the cells grow much more rapidly in vitro, form colonies in soft agar and display branching morphogenesis in matrigel cultures, all of which underscore their increased propensity to form tumors in nude mice and to metastasize (Jeers et al., 1996b) . For dierential display screening, we compared cDNAs isolated from parental SK-LMS cells to those isolated from a pool of SK-LMS cells stably expressing exogenous HGF/SF; cDNA fragments that were dierentially displayed in the initial screening (data not shown) were then used as probes for Northern analyses to verify the expression patterns ( Figure 1a ). In the presence of HGF/SF, we identi®ed marked decreases in ®bronectin, TGFb1, and ferritin heavy chain mRNA levels, and increases in aspartyl b-hydroxylase mRNA levels ( Figure 1a) . In subsequent studies, we speci®cally addressed the decreases in ®bronectin and TGFb1 expression.
To determine whether Met-HGF/SF autocrine signaling resulted in decreases in ®bronectin and TGFb1 mRNA expression in other types of cells, we a b c Figure 1 The eect of Met-HGF/SF signaling on ®bronectin expression. Total cellular RNA was isolated from (a) parental SK-LMS cells (control) and SK-LMS cells that stably expressed HGF/SF; (b) parental C127 cells (Control), and C127 cells that stably expressed the mouse Met cDNA (Met mu ) and the human HGF cDNA (HGF hu ); or (c) SK-LMS cells maintained in 10% (v/v) FCS/DMEM that were exposed to one dose of HGF (200 U/mL) for the indicated times. For each experiment, total cellular RNA was isolated and used for Northern blotting. The blots were sequentially probed with the indicated cDNA probes; the sequences of the probes are available on request. The positions of the major ribosomal RNA species are indicated at the left examined expression of the mRNAs in C127 mouse ®broblasts. These cells normally do not express Met or HGF/SF, but become highly transformed and metastatic when they stably express Met and its ligand ectopically (Jeers et al., 1996c) . We observed a marked decrease in ®bronectin expression in C127 cells stably expressing exogenous Met and HGF ( Figure 1b) ; however, we did not observe a change in TGFb1 mRNA levels (data not shown). We also examined U-118 and U-138 human glioblastoma cells for ®bronectin expression; these cells express endogenous Met-HGF/SF autocrine loops that have been implicated in their transformation (Koochekpour et al., 1997) . When we blocked Met-HGF/SF signaling in the glioblastoma cells with a neutralizing HGF/SF antibody, we observed an increase in ®bronectin mRNA and protein production (data not shown). Thus in three distinct tumor systems, leiomyosarcoma cells, C127 cells, and glioma cells, a major consequence of Met-HGF/SF signaling was down-regulation of ®bronectin expression.
We also examined the eect of transient Met-HGF/ SF signaling on ®bronectin mRNA expression ( Figure  1c ). When SK-LMS cells were exposed to a single dose of HGF/SF, ®bronectin mRNA levels actually showed an increase within 30 min that remained elevated for about 8 h. However, the ®bronectin levels decreased to below basal levels by 24 h and to even lower levels by 48 and 72 h. Similarly, when the cells were exposed to three doses of HGF at 24 h intervals, the ®bronectin levels were reduced to well below basal levels ( Figure  1c) . Thus, it was only constitutive or long-term exposure that caused marked decreases in ®bronectin expression. In Western blotting experiments, we found decreases in ®bronectin protein levels that paralleled those in ®bronectin mRNA (data not shown and Figure 4) .
Although the decrease in TGFb1 expression by Met-HGF/SF signaling was not found in all cell types, we considered it a potentially important phenomenon in SK-LMS cells, given that TGFb1 is known to stimulate production of ®bronectin (Ignotz and Massague, 1986) and reduced TGFb1 levels might lead to decreases in ®bronectin production. To determine if TGFb1 levels did in¯uence ®bronectin levels in SK-LMS cells, cells expressing HGF/SF were exposed to exogenous TGFb1 for 24 h. Under these conditions, TGFb1 caused a partial restoration of ®bronectin production (Figure 2 ), suggesting that HGF/SF and TGFb1 acted as antagonistic factors in determining ®bronectin production, and that the eect of TGFb1 was dominant but not absolute. We measured Met levels in the cells following exposure to TGFb1, but they were not altered (data not shown).
Next we examined ®bronectin production in tumors that arose from SK-LMS cells injected into nude mice. We found marked decreases in ®bronectin mRNA levels that were even lower than those in SK-LMS/ HGF cells (Figure 3) . The decreases in ®bronectin expression may have been, in part, due to increased Met-HGF/SF signaling, since Met and HGF/SF mRNA levels were slightly elevated (Figure 3) .
We also examined ®bronectin levels in tumors that arose in nude mice following injection of SK-LMS/ HGF cells; these cells form tumors much more rapidly than the parental SK-LMS cells, and they metastasize to the lungs whereas the parental cells do not (Jeers et al., 1996b) . We found that ®bronectin levels in SK-LMS/HGF tumor cell explants were lower than those in the injected cell (Figure 3 ). In addition, ®bronectin levels in SK-LMS/HGF lung metastases were as low or slightly lower than those of the tumors from which they metastasized (not shown).
Finally, we investigated whether re-establishing high ®bronectin production in cells transformed by Met-HGF/ SF would aect tumorigenesis or metastasis. We stably transfected C127-Met-HGF cells with a human fibronectin expression vector and isolated three clonal cell lines; ®bronectin protein levels in each line were equal to or greater than those in parental C127 cells (Figure 4) . Expression of exogenous ®bronectin did not markedly aect the morphology, cell cycle distribution, or overall growth rate of C127-Met-HGF cells (not shown). In addition, ®bronectin did not aect the ability of the C127-Met-HGF cells to grow invasively in three-dimensional matrigel cultures (Jeers et al., 1996b) (not shown). However, ®bronectin did partially inhibit soft-agar colony formation by the cells: the three C127-Met-HGF-FN cell lines formed about one-third fewer soft agar colonies than C127-Met-HGF cells (data not shown). We also examined the ability of the cells to form tumors and to metastasize in nude mice; however, C127-Met-HGF and C127-Met-HGF-FN cells formed subcutaneous tumors at the same rate, and both readily metastasized to the lungs (not shown). We veri®ed that the C127-Met-HGF-FN tumors maintained high ®bronectin Taking these data together, we conclude that Met-HGF/SF signaling causes a marked decrease in ®bronectin production, and while this may contribute to tumorigenesis and metastasis (see Giancotti and Mainiero, 1994; Hynes, 1990; Ruoslahti, 1984) , it does not seem essential for either process in our systems. Our results contrast with those of a recent study by Akamatsu et al. (1996) , who showed that in HT1080 human ®brosarcoma cells, overexpression of fibronectin delays the onset of tumor formation in nude mice, with the amount of delay varying directly with the amount of ®bronectin expressed by the cells. The discrepancy between these two studies may re¯ect the dierence in the transforming oncogene in the two cell systems. Met-HGF/SF probably trigger multiple pathway that contribute to tumorigenesis and metastasis, and blocking only one pathway may not be enough to completely inhibit tumor formation. We cannot rule out that in our assays, human ®bronectin did not substitute for mouse ®bronectin in the C127 mouse cells.
Reduced ®bronectin production may contribute to tumorigenic growth in at least two ways: removal of a structural network from around the cell that serves as a restraint to growth, or alternatively, reduction of ®bronectin/integrin signaling and consequent modulation of cellular growth pathways. Recent studies supporting the second possibility have shown that engagement of a subset of b 1 and a v integrins by ®bronectin stimulates the MAP kinase pathway and cell cycle progression via Shc; conversely, engagement of dierent integrins by other extracellular glycoproteins not linked to Shc, does not activate the MAP kinase pathway, and leads to cell cycle exit and apoptosis (Wary et al., 1996) . Therefore, the array of glycoproteins displayed on a cell's surface determines the particular intracellular growth pathways that are stimulated, and it is thus critically important in sustaining normal cellular growth characteristics.
In our experiments, we found that not only primary tumors, but also their metastases showed reduced ®bronectin production. Promotion of metastasis by Met/HGF signaling (Rong et al., 1994 ) is thought to occur by increasing cell motility, angiogenesis (Grant et al., 1993) , and the production of extracellular matrix proteases (Jeers et al., 1996b; Pepper et al., 1992) . Modulation of extracellular glycoprotein production may be yet another means by which metastasis is promoted. Although our results do not address which stage of metastasis is promoted by low ®bronectin, the promotion may well be at the level of cell migration. Clearly some adhesion is necessary for cellular migration, and this would in fact require the presence of ®bronectin. However, it has been suggested that moderate adhesion of cells to a loosely organized extracellular matrix would facilitate their migration, while tighter adhesion to a well-formed extracellular matrix would prevent it (Giancotti and Mainiero, 1994) . Our results only addressed the steady-state levels of ®bronectin secreted by SK-LMS cells; it is possible that transient¯uctuations in ®bronectin production are necessary for metastasis, and this possibility should be examined.
We also showed that Met-HGF/SF caused a decrease in TGFb1 expression in SK-LMS cells, and that the decrease in TGFb1 was important in establishing low ®bronectin expression in those cells. The fact that we did not see a similar TGFb1 decrease in C127 cells argues that Met/HGF signaling clearly has independent means of reducing ®bronectin expression. However, the results in SK-LMS cells indicate that HGF/SF and TGFb are antagonistic factors, and that their relative concentrations is critical in determining the growth characteristics of these cells. Other investigators have shown that the same is true in other cell systems: in human lung ®broblasts and mink lung epithelial cells, HGF/SF stimulates cell growth, while TGFb inhibits it (Taipale and Keski-Oja, 1996) ; similarly, in canine kidney cells, HGF/SF strongly stimulates branching in matrigel, while TGFb inhibits it (Santos and Nigam, 1993) . Since the HGF/SF-TGFb balance is so critical in determining cell growth and dierentiation, regulating this balance externally could be an eective therapy for some cancers.
